COSA 2014* , ,
Presentations this author is a contributor to:
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-Programmed Death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). (#412)
3:00 PM
Mario Sznol
Poster discussion 2
Ipilimumab versus placebo after complete resection of stage III melanoma: efficacy and safety results from the EORTC 18071 phase III trial (#374)
3:00 PM
Alexander M Eggermont
Poster discussion 2